CeQur said today that it acquired a wearable, on-demand insulin delivery system from Johnson & Johnson‘s (NYSE:JNJ) Calibra Medical for an undisclosed amount.
The Calibra device is designed to dose rapid-acting, mealtime insulin for people with Type II diabetes. In a 278-person study, use of the Calibra device resulted in higher ease-of-use and patient satisfaction scores, as well as less glycemic variability compared to insulin injection pens.
Get the full story at our sister site, Drug Delivery Business News.